Xavier Cansouline has a total of 37 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Current real-life survival after segmentectomy for lung cancer

    by Xavier Cansouline, Abdoul-Khadry Gassama, Abdelhakim Elmraki, Béatrice Lipan, Damien Sizaret, Delphine Carmier, Antoine Legras

    Introduction: Segmentectomy for non-small cell lung cancer (NSCLC) is increasingly performed for small-sized lesions. However, prognostic factors associated with poor outcomes after this lung-sparing oncologic surgery remain uncertain. Methods: We conducted a single-center retrospective study including 100 consecutive patients who underwent single or multiple segmentectomies for NSCLC in real-world practice. Results: In univariate analyses, compromise segmentectomy (HR 3.52; p = 0.005), complex segmentectomy (HR 2.56; p = 0.020), SUVmax ≥ 6 (HR 2.86; p = 0.017), and thoracotomy (HR 2.62; p = 0.020) were associated with worse overall survival. In multivariable analysis, compromise segmentectomy remained associated with worse overall survival (HR 3.47; p = 0.026). Regarding recurrence, thoracotomy was associated with poorer disease-free survival (HR 2.77; p = 0.040). Conclusion: In this real-world cohort, compromise segmentectomy identified a high-risk subgroup with impaired overall survival, probably reflecting baseline frailty and comorbidity rather than a clearly demonstrated increase in recurrence. These findings support careful preoperative selection and counseling of patients considered for lung-sparing resection outside standard indications.

  • Open Access

    Overall survival of ADAURA: game, set, and match?

    by Xavier Cansouline, Damien Sizaret, Beatrice Lipan, Anne Tallet, Delphine Carmier, Antoine Legras

    Overall survival of ADAURA: game, set, and match?

  • Surgery of primary lung carcinoid tumors at metastatic stage: A national study from the French Group of Endocrine Tumors (GTE) and ENDOCAN‐RENATEN network

    by Lucie Duponchelle, Eric Baudin, Fabien Subtil, Christine Do Cao, Eric Dansin, Marine Perrier, Marie‐Pierre Teissier, Magalie Haissaguerre, Xavier Cansouline, Julien Hadoux, et al.

    The outcome following surgery for patients with primary lung neuroendocrine tumors at metastatic stage remains poorly characterized. We conducted a retrospective national study including patients with metastatic lung neuroendocrine tumors at diagnosis. We performed a safety study to evaluate major morbidity and mortality of surgical resection of the primary tumor and compared patients in the operative to the nonoperative group. A total of 155 patients were included: 41 in the operative group and 114 in the nonoperative group, median age was 64 years. Metastases were mainly located in the liver (74.2%) and the bone (49.7%). The primary endpoint was met as the rate of major complications was 4.9% and there was no postoperative mortality. In the operative group 42.5% of patients had improvement of their pulmonary symptoms versus 14.4% in the nonoperative group. The median overall survival was not reached in the operative group and was 4.3 years (95% CI [3.5;4.9]) in the nonoperative group (univariate analysis, HR = 0.42 95% CI [0.23–0.77], p = .002). After multivariate analysis, only an ECOG‐PS ≥1 (vs. 0, HR = 2.44, 95% CI [1.46;4.07], p = .001) and >1 metastatic site (vs. 1; HR = 1.83, 95% CI [1.06;3.16], p = .030) remained significantly associated with overall survival. The resection of the primary tumor was not significantly associated with overall survival (HR = 0.63, 95% CI [0.32;1.24], p = .183). In conclusion, surgery of primary lung neuroendocrine tumors at metastatic stage is a safe option that should be considered in selected patients in order to improve symptoms with a view to improving their quality of life. Larger studies are warranted to evaluate the impact of surgery on survival.


  • Open Access

    Surgery of Primary Lung Carcinoid Tumors at Metastatic Stage: A National Study from the French Group of Endocrine Tumors (GTE) and ENDOCAN-RENATEN Network

    by Lucie Duponchelle, Eric Baudin, Fabien Subtil, Christine Do Cao, Eric Dansin, Marine Perrier, Marie-Pierre Teissier, Magalie Haissaguerre, Xavier Cansouline, Julien Hadoux, et al.

    Introduction: The outcome of the primary lung neuroendocrine tumors surgery at metastatic stage remains poorly characterized. Methods: We conducted a retrospective national study including patients with metastatic lung neuroendocrine tumors at diagnosis. We performed a safety study to evaluate major morbidity and mortality of surgical resection of the primary tumor, and compared data in operative and non-operative group. Results: A total of 155 patients were included, 41 in the operative group and 114 in the non-operative group. The median age was 64 years. Metastases were mainly located in the liver (74.2%) and the bone (49.7%). The primary end-point was met as the rate of major complications was 4.9% and there was no post-operative mortality. In the operative group 42.5% of patients had improvement of their pulmonary symptoms, versus only 14.4% in the non-operative group. The median overall survival was not reached in the operative group and 4.3 years (95%CI [3.5;4.9]) in the non-operative group (univariate analysis, HR=0.42 95%CI [0.23;0.77], p=0.002). After multivariate analysis, only an ECOG-PS ≥1 (versus 0, HR=2.44, 95%CI [1.46;4.07], p=0.001) and >1 metastatic site (versus 1; HR=1.83, 95%CI [1.06;3.16], p=0.030) remained significantly associated with overall survival. The resection of the primary tumor was not significantly associated with OS (HR=0.63, 95%CI [0.32;1.24], p=0.183). Conclusions: Surgery of the primary lung neuroendocrine tumors at metastatic stage is a safe option that should be considered in selected patients in order to improve symptoms, with a view to improve their quality of life. Larger studies are warranted to evaluate the impact of surgery on survival.

  • Open Access

    EGFR-Mutant Non-Small-Cell Lung Cancer at Surgical Stages: What Is the Place for Tyrosine Kinase Inhibitors?

    by Xavier Cansouline, Béatrice Lipan, Damien Sizaret, Anne Tallet, Christophe Vandier, Delphine Carmier, Antoine Legras

    The ADAURA trial has been significant for the perception of EGFR tyrosine kinase inhibitors (TKIs) as a tool for early stage non-small-cell lung cancer (NSCLC). It produced such great insight that the main TKI, Osimertinib, was rapidly integrated into international guidelines for adjuvant use. However, EGFR-mutant NSCLC is a complex entity and has various targeting drugs, and the benefits for patients might not be as clear as they seem. We reviewed trials and meta-analyses considering TKI adjuvant and neoadjuvant use. We also explored the influence of mutation variability and financial evaluations. We found that TKIs often show disease-free survival (DFS) benefits, yet studies have struggled to improve the overall survival (OS); however, the results from the literature might be confusing because of variability in the stages and mutations. The safety profiles and adverse events are acceptable, but costs remain high and accessibility might not be optimal. TKIs are promising drugs that could allow for tailored treatment designs.


  • Management of antibody mediated rejection (AMR) in heart transplant patients: The real world in a French single center treating all pathological AMR

    by Emmanuelle Vermes, Xavier Cansouline, Lucile Rouault, Marc Antoine May, Claudia Loardi